P16 as a molecular biomarker of cervical adenocarcinoma

American Journal of Obstetrics and Gynecology

Volumn 190, Issue 3, 2004, Pages 668-673

  Schorge, John O ^a   Lea, Jayanthi S ^a   Elias, Keren J ^a   Rajanbabu, Ramababu ^a   Coleman, Robert L ^a   Miller, David S ^a   Ashfaq, Raheela ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Adenocarcinoma in situ; Biomarker; Cervical adenocarcinoma; P16

Indexed keywords

BIOLOGICAL MARKER; CYCLIN D1; CYCLIN E; KI 67 ANTIGEN; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; VIRUS DNA;

ADENOCARCINOMA; ARTICLE; CARCINOMA IN SITU; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE CERVIX CARCINOMA; WART VIRUS; WESTERN BLOTTING;

EID: 1642505577     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2003.09.038     Document Type: Article

References (25)

1. Vizcaino AP, Moreno V, Bosch FX, Munoz N, Barros-Dios XM, Parkin DM. International trends in the incidence of cervical cancer: I, adenocarcinoma and adenosquamous cell carcinomas. Int J Cancer 1998;75:536-45.
2. Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States - a 24-year population-based study. Gynecol Oncol 2000;78:97-105.
3. Lee KR, Flynn CE. Early invasive adenocarcinoma of the cervix. Cancer 2000;89:1048-55.
4. Schorge JO, Saboorian MH, Hynan L, Ashfaq R. ThinPrep detection of cervical and endometrial adenocarcinoma: a retrospective cohort study. Cancer 2002;96:338-43.
5. Bai H, Sung CJ, Steinhoff MM. ThinPrep Pap test promotes detection of glandular lesions of the endocervix. Diagn Cytopathol 2000;23:19-22.
6. McCluggage WG. Endocervical glandular lesions: controversial aspects and ancillary techniques. J Clin Pathol 2003;56:164-73.
7. Cameron RI, Maxwell P, Jenkins D, McCluggage WG. Immunohistochemical staining with MIB1, bcl-2, and p16 assists in the distinction of cervical glandular intraepithelial neoplasia from tubo-endometrial metaplasia, endometriosis and microglandular hyperplasia. Histopathology 2002;41:313-21.
8. Cina SJ, Richardson MS, Austin RM, Kurman RJ. Immunohistochemical staining for Ki-67 antigen, carcinoembryonic antigen, and p53 in the differential diagnosis of glandular lesions of the cervix. Mod Pathol 1997;10:176-80.
9. Lu X, Toki T, Konishi I, Nikaido T, Fujii S. Expression of p21WAF1/CIP1 in adenocarcinoma of the uterine cervix. Cancer 1998;82:2409-17.
10. Milde-Langosch K, Riethdorf S, Kraus-Poppinghaus A, Riethdorf L, Loning T. Expression of cyclin-dependent kinase inhibitors p16MTS1, p21WAF1, and p27KIP1 in HPV-positive and HPV-negative cervical adenocarcinomas. Virchows Arch 2001;439: 55-61.
11. Clarke B, Chetty R. Cell cycle aberrations in the pathogenesis of squamous cell carcinoma of the uterine cervix. Gynecol Oncol 2001;82:238-46.
12. Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
13. Stoler MH. Human papillomavirus and cervical neoplasia: a model for carcinogenesis. Int J Gynecol Pathol 2000;19:16-28.
14. Gravitt PE, Peyton CL, Alessi TQ, Wheeler Cm, Coutlee F, Hildesheim A, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000;38:357-61.
15. Negri G, Egarter-Vigl E, Kasal A, Romano F, Haitel A. Mian C. p16INK4a is a useful marker for the diagnosis of adenocarcinoma of the cervix uteri and its precursors. Am J Surg Pathol 2003;27: 187-93.
16. Riethdorf L, Riethdorf S, Lee KR, Cviko A, Loning T, Crum CP. Human papillomaviruses, expression of p16, and early endocervical glandular neoplasia. Hum Pathol 2002;33:899-904.
17. Keating JT, Cviko A, Reithdorf S, Riethdorf L, Quade BJ, Sun D, et al. Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol 2001;25:884-91.
18. Bibbo M, Klump WJ, DeCecco J, Kovatich AJ. Procedure for immunocytochemical detection of P16INK4A antigen in thin-layer, liquid-based specimens. Acta Cytol 2002;46:25-9.
19. Pirog EC, Kleter B, Olgac S, Bobkiewicz P, Lindeman J, Quint WGV, et al. Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. Am J Pathol 2000;157:1055-62.
20. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87:796-802.
21. Park JS, Hwang ES, Park SN, Ahn HK, Um SJ, Kim CJ, et al. Physical status and expression of HPV genes in cervical cancers. Gynecol Oncol 1997;65:121-9.
22. Nakao Y, Yang X, Yokoyama M, Ferenczy A, Tang SC, Pater MM, et al. Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. Br J Cancer 1997;75:1410-6.
23. Goldstein NS, Ahmad E, Hussain M, Hankin RC, Perez-Reyes N. Endocervical glandular atypia: does a preneoplastic lesion of adenocarcinoma in situ exist? Am J Clin Pathol 1998;110:200-9.
24. Kim JW, Namkoong SE, Ryu SW, Kim HS, Shin JW, Lee JM, et al. Absence of p15INK4B and p16INK4A gene alterations in primary cervical tissues and cell lines with human papillomavirus infection. Gynecol Oncol 1998;70:75-9.
25. Cho NH, Kim YT, Kim JW. Correlation between G1 cyclins and HPV in the uterine cervix. Int J Gynecol Pathol 1997;16: 339-47.